融资融券数据显示，该股最新（11月21日）两融余额为8.69亿元，其中，融资余额为8.67亿元，融券余 额为171.41万元。近5日融资余额合计减少6276.78万元，降幅为6.75%。融券余额合计减少77.36万元， 降幅31.10%。 10月30日公司发布的三季报数据显示，前三季度公司共实现营业收入10.92亿元，同比下降9.41%，实现 净利润1.08亿元，同比下降19.18%。（数据宝） 中源协和11月24日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 开源证券股份有限公司西安西大街证券营业部 | 4217.02 | | | 买二 | 沪股通专用 | 3700.57 | | | 买三 | 东吴证券股份有限公司常熟商城中路证券营业部 | 1712.55 | | | 买四 | 华鑫证券有限责任公司上海宛平南路证券营业部 | 1217.98 | | | 买五 | 中信证券股份有限公司上海分公司 | 820.58 | | | 卖一 | 沪股通专用 | | 2614.21 ...

Core Insights - The precision medicine sector experienced a 1.92% increase on November 24, with Guomai Technology leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Guomai Technology (002093) closed at 12.19, up 10.02% with a trading volume of 446,600 shares and a transaction value of 536 million [1] - Zhongyuan Xiehe (600645) also rose by 10.02% to 28.23, with a trading volume of 169,100 shares and a transaction value of 468 million [1] - Other notable performers include: - Toukeng Life (300642) at 19.51, up 3.34% [1] - Beirui Gene (000710) at 11.97, up 3.28% [1] - Yangjin Medical (300030) at 7.90, up 3.27% [1] Capital Flow - The precision medicine sector saw a net inflow of 526 million from institutional investors, while retail investors experienced a net outflow of 143 million [2] - The main capital inflow and outflow for key stocks include: - WuXi AppTec (603259) with a net inflow of 251 million [3] - Guomai Technology (002093) with a net inflow of 241 million [3] - Zhongyuan Xiehe (600645) with a net inflow of 102 million [3]

AI and Technology - Google has released a new image model, attracting attention in the AI sector [2] - 360, a leader in AI search, has developed the 360 Smart Brain with ten core capabilities and hundreds of detailed functions, reporting a net loss of 120 million in Q3, narrowing from mid-year losses [2] - Jiuxi Software has launched its new generation large model application management platform, Nvwa GPT, which integrates and provides capabilities for large model management and intelligent orchestration [2] Aerospace and Defense - Japan has announced the deployment of missiles in sensitive areas, impacting defense-related companies [2] - Aerospace Power, a subsidiary of the Aerospace Science and Technology Group, has seen stock performance with a recent increase [2] - China Shipbuilding Industry Group, which controls multiple defense-related companies, is the only military ship production base in South China [2] E-commerce and Retail - Alibaba's "Qianwen" app has surpassed 10 million downloads in its first week of public testing [3] - Sanjiang Shopping, the largest local supermarket chain in Zhejiang, has Alibaba as its second-largest shareholder and is involved in the sale of prepared dishes [3] - DataPort, a leading data center company, provides infrastructure solutions and serves major internet companies like Alibaba, Tencent, Baidu, and NetEase [3] Real Estate - Multiple regions have issued notifications to promote the stable and healthy development of the real estate market [5] - Everbright Jiabao, a real estate development company under Everbright Group, focuses on non-performing asset management in Zhejiang [5] Automotive - GAC Group has officially launched its all-solid-state battery pilot production line [5] - Jinlong Automobile, a major bus manufacturer, has partnered with Baidu to produce China's first commercial-grade autonomous micro-circulation vehicle [5] Renewable Energy - Guosheng Technology, a top global manufacturer of heterojunction products, is focusing on high-efficiency solar cells and has plans for a solid-state battery project [6] - Hemei Group's subsidiary is investing in a green hydrogen project with an estimated total investment of around 700 million [6] Food and Beverage - Xinhua Du, a leading e-commerce platform for liquor, has seen stock performance with a recent increase [4] - Hasi Lian, a beauty brand, is focusing on skincare products and has developed a series of medical-grade dressings [5]

Group 1 - The core viewpoint of the articles highlights the active performance of the medical device sector, with the medical device ETF (562600) rising by 0.92% and achieving net inflows for 19 consecutive trading days, totaling over 148 million yuan [1] - Major industry players are engaging in capital acquisition, with companies like Jiuzhoutong and Guangzhou Pharmaceutical Group making significant investments in leading firms, indicating a trend of industry consolidation [1] - China Galaxy Securities anticipates that the medical industry will undergo systematic reforms, with policies expected to drive innovation and quality improvements, particularly in the context of the 14th Five-Year Plan [1] Group 2 - The medical device industry is experiencing robust growth, and the medical device ETF (562600) tracks a representative index of 100 companies, with a high concentration of 89.3% in the medical device sector, making it an effective tool for capturing growth opportunities [2] - Investors can also consider alternative options such as the 华夏中证全指医疗器械ETF发起式联接A (021250) and 华夏中证全指医疗器械ETF发起式联接C (021251) for convenient investment in the sector [2]

（文章来源：证券日报） 证券日报网讯中源协和11月20日在互动平台回答投资者提问时表示，截至2025年9月30日股东人数为 34694户。 ...

Core Viewpoint - Zhongyuan Union's stock price has experienced fluctuations, with a year-to-date increase of 36.32% but a recent decline of 6.93% over the past five trading days [2] Company Overview - Zhongyuan Union, established on June 14, 1995, and listed on May 4, 1993, is located in Tianjin Binhai High-tech Zone. The company specializes in cell detection preparation and storage, in vitro diagnostic materials, reagents, and equipment, as well as gene testing services and clinical applications of stem cells and immune cells [2] - The main business revenue composition includes: testing reagents (58.46%), cell detection preparation and storage (26.49%), research reagents (11.86%), gene testing (2.40%), and others (0.79%) [2] Financial Performance - For the period from January to September 2025, Zhongyuan Union achieved operating revenue of 1.092 billion yuan, a year-on-year decrease of 9.41%, and a net profit attributable to shareholders of 108 million yuan, down 19.18% year-on-year [2] - Cumulative cash dividends since A-share listing amount to 37.5405 million yuan, with no dividends distributed in the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 4.06% to 34,700, with an average of 13,482 circulating shares per person, a decrease of 3.91% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 15.25 million shares (an increase of 902,300 shares), and Huabao Zhongzheng Medical ETF, holding 10.5688 million shares (a decrease of 1.5141 million shares) [3]

Group 1 - The restructuring protein concept declined by 1.71%, ranking among the top declines in the concept sector, with notable declines in stocks such as Kexing Pharmaceutical, Haoyuan Pharmaceutical, and Zejing Pharmaceutical [1] - Among the stocks in the restructuring protein concept, 8 stocks saw price increases, with *ST Wanfang, ST Weiming, and Lideman leading with increases of 4.96%, 2.21%, and 1.76% respectively [1] - The restructuring protein concept experienced a net outflow of 742 million yuan from main funds today, with 38 stocks seeing net outflows, and 8 stocks with outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock in the restructuring protein concept was Heyuan Biological, with a net outflow of 82.99 million yuan, followed by Sangfor Guojian, Zhifei Biological, and Zhongyuan Xiehe with net outflows of 59.97 million yuan, 57.83 million yuan, and 56.32 million yuan respectively [2][3] - The stocks with the highest net inflow included *ST Wanfang, Furuida, and Yinuote, with net inflows of 10.67 million yuan, 8.92 million yuan, and 7.75 million yuan respectively [4]

2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年11月14日 证券代码：600645 证券简称：中源协和 公告编号：2025-045 中源协和细胞基因工程股份有限公司 (二)股东大会召开的地点：天津市滨海高新区华苑产业区梅苑路12号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等。 会议采用现场投票和网络投票相结合的表决方式，符合《公司法》和《公司章程》的有关规定，经公司 半数以上董事推举，本次股东大会由副董事长、总经理WANG HONGQI（王洪琦）先生主持。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席3人，董事长龚虹嘉先生、副董事长王勇先生、董事吴珊女士和李旭先生、 独立董事裴端卿先生和侯欣一先生因工作原因未能出席本次会议； 2、公司在任监事3 ...

证券代码：600645 证券简称：中源协和 公告编号：2025-045 中源协和细胞基因工程股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 11 月 14 日 (二)股东大会召开的地点：天津市滨海高新区华苑产业区梅苑路 12 号公司会议 室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 272 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 112,339,247 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 24.6414 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等。 会议采用现场投票和网络投票相结合的表决方式，符合《公司法》和《公司 表决情况： | 股东类型 | 同意 | | ...

邮编· 100005 传真:010-66090016 电话:010-88004488/66090088 北京国枫律师事务所 关于中源协和细胞基因工程股份有限公司 2025 年第一次临时股东大会的 法律意见书 国枫律股字[2025]A0560 号 致：中源协和细胞基因工程股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托,指派律师出席并见 证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》(以下简称 "《股东会规则》")、《律师事务所从事证券法律业务管理办法》(以下简称"《证券法律 业务管理办法》")、《律师事务所证券法律业务执业规则（试行)》(以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《中源协和细胞基因 工程股份有限公司章程》(以下简称"《公司章程》")的规定,就本次会议的召集与召开 程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律 意见书。 对本法律意见书的出 ...